循环脂肪因子与1型糖尿病女性子痫前期相关
本研究在1型糖尿病孕妇前瞻性队列中检测瘦素、FABP4、脂联素(总及HMW)、RBP4和抵抗素,发现子痫前期组早在孕早期即出现提示胰岛素抵抗的脂肪因子谱改变,且这些关联独立于BMI。
要点
- 1型糖尿病孕妇孕早期瘦素及其与脂联素比值升高、总脂联素降低,与后续子痫前期相关。
- 孕中晚期上述关联持续,子痫前期组FABP4亦升高。
- 校正HbA1c、胰岛素用量和孕周后,瘦素、瘦素与总脂联素比值及FABP4对子痫前期有预测关联,且独立于BMI。
核心结论
- 1型糖尿病女性早在孕早期即出现提示胰岛素抵抗的脂肪因子谱,与后续子痫前期相关,可能反映孕前即存在的母体特征;这些关联在孕中晚期持续且独立于BMI;胰岛素抵抗可能使1型糖尿病女性易患子痫前期。
研究设计与样本
- 来自已建立的1型糖尿病孕妇前瞻性队列,研究23例发生子痫前期者和24例血压保持正常者,并纳入19例健康非糖尿病血压正常孕妇作为参考值。
- 血浆脂肪因子采用ELISA测定,样本来自三个研究访视(访视1至访视3),平均孕周分别为12.4±1.8周、21.7±1.4周和31.4±1.5周。
- 所有孕妇入组时均无微量白蛋白尿和高血压,所有研究访视均早于子痫前期临床发病。
主要发现
- 所有组中,瘦素、瘦素与总或HMW脂联素比值、FABP4浓度、FABP4与总或HMW脂联素比值及抵抗素水平随孕周升高,总及HMW脂联素随孕周下降。
- 访视1时,后续发生子痫前期的糖尿病女性较未发生者瘦素、瘦素与总或HMW脂联素比值、FABP4与总或HMW脂联素比值升高(p<0.05),总脂联素降低(p<0.05)。
- 访视1时,血压正常的糖尿病女性较非糖尿病女性总脂联素升高(p<0.05)。
- 访视2和3时,两个糖尿病组间的主要差异持续存在,子痫前期组FABP4亦升高(p<0.05);两个血压正常组间无差异。
- 校正协变量(HbA1c、胰岛素kg-1 day-1和孕周)后logistic回归分析中,子痫前期的最佳预测模型为:访视1瘦素加倍OR 9.0(p<0.01);访视2瘦素与总脂联素比值加倍OR 3.7(p<0.05);访视3 FABP4浓度加倍OR 25.1(p<0.01);这些关联独立于BMI。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The incidence of pre-eclampsia, a multisystem disorder of pregnancy, is fourfold higher in type 1 diabetic than non-diabetic women; it is also increased in women with features of the metabolic syndrome and insulin resistance. In a prospective study of pregnant women with type 1 diabetes, we measured plasma levels of adipokines known to be associated with insulin resistance: leptin, fatty acid binding protein 4 (FABP4), adiponectin (total and high molecular weight [HMW]; also known as high molecular mass), retinol binding protein 4 (RBP4) and resistin and evaluated associations with the subsequent development of pre-eclampsia. METHODS: From an established prospective cohort of pregnant type 1 diabetic women, we studied 23 who developed pre-eclampsia and 24 who remained normotensive; for reference values we included 19 healthy non-diabetic normotensive pregnant women. Plasma adipokines were measured (by ELISA) in stored samples from three study visits (Visit 1- Visit 3) at different gestational ages (mean ± SD): Visit 1, 12.4 ± 1.8 weeks; Visit 2, 21.7 ± 1.4 weeks; and Visit 3, 31.4 ± 1.5 weeks. All the women were free of microalbuminuria and hypertension at enrolment. All study visits preceded the clinical onset of pre-eclampsia. RESULTS: In all groups, leptin, the ratio of leptin to total or HMW adiponectin, FABP4 concentration, ratio of FABP4 to total or HMW adiponectin and resistin level increased, while total and HMW adiponectin decreased, with gestational age. At Visit 1: (1) in diabetic women with vs without subsequent pre-eclampsia, leptin, ratio of leptin to total or HMW adiponectin, and ratio of FABP4 to total or HMW adiponectin, were increased (p < 0.05), while total adiponectin was decreased (p < 0.05); and (2) in normotensive diabetic vs non-diabetic women, total adiponectin was elevated (p < 0.05). At Visits 2 and 3: (1) the primary findings in the two diabetic groups persisted, and FABP4 also increased in women with subsequent pre-eclampsia (p < 0.05); and (2) there were no differences between the two normotensive groups. By logistic regression analyses after covariate adjustment (HbA1c, insulin kg-1 day-1 and gestational age), the best predictive models for pre-eclampsia were as follows: Visit 1, doubling of leptin, OR 9.0 (p < 0.01); Visit 2, doubling of the leptin:total adiponectin ratio, OR 3.7 (p < 0.05); and Visit 3, doubling of FABP4 concentration, OR 25.1 (p < 0.01). The associations were independent of BMI. CONCLUSIONS/INTERPRETATION: As early as the first trimester in type 1 diabetic women, adipokine profiles that suggest insulin resistance are associated with subsequent pre-eclampsia, possibly reflecting maternal characteristics that precede pregnancy. These associations persist in the second and third trimesters, and are independent of BMI. Insulin resistance may predispose women with type 1 diabetes to pre-eclampsia.
引用
- Kelly CB, Hookham MB, Yu JY, et al. Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes. Diabetologia. 2017. PMID: 28875223. doi:10.1007/s00125-017-4415-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。